Our Science
Our Science

Pioneering the unseen.
Our comprehensive investigation into the pathophysiology of androgenic alopecia has revealed a range of complex mechanisms contributing to hair loss and thinning.
In response, we focused on the development of targeted molecules designed to address each of these mechanisms individually.
Each molecule underwent extensive preclinical and clinical testing to confirm
both efficacy and safety, with the results published in 2024.
Development History
2022~2024
- Human clinical trial
2021~2022
- in-vivo / ex-vivo efficacy evaluation
2021
- Target molecule development
- Disease MoA (Mechanism of Action) identification
TrinogeniX™ in detail and its clinical benefits
TrinogeniX™ in detail and its clinical benefits
Renovozol, a GPR44 antagonist, stimulates hair growth by elongating anagen period with blocking the action of prostaglandin D2 (PGD2), which is known to inhibit hair growth.
Renovoridine, a glycogen phosphorylase enzyme inhibitor, stimulates hair growth by inhibiting catagen entry with modulating energy metabolism and blocking reactive oxygen species (ROS).